Patidegib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Patidegib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Patidegib can convert its Small molecule drug profile and SMO biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Patidegib (query alias: Patidegib) |
|---|---|
| Modality / target | Small molecule drug; SMO; SMO antagonists, Hedgehog cell-signalling pathway inhibitors |
| Highest global status | Phase 3 |
| Originator | Infinity Pharmaceuticals, Inc. |
| Active developers | Sol-Gel Technologies Ltd. |
The MCP disease footprint includes Basal Cell Nevus Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| EUCTR2020-000253-27-BE | Phase 3 | Prematurely Ended | 200 | The number of facial BCCs removed by surgery is considered an appropriate study endpoint as surgery has significant morbidity in Gorlin Syndrome (e.g., scarring, functional loss of eyelid, nose, ear). |
| NCT06050122 | Phase 3 | Active, not recruiting | 140 | Number of new BCCs on the face at Month 12 |
| NCT04308395 | Phase 3 | Terminated | 108 | Incidence of Treatment-emergent Adverse Events (TEAEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Patients With Non-Gorlin High Frequency BCC
Phase 2; n=50; evaluation: not stated. Reported fields: Number of Participants With Treatment-emergent Adverse Events (TEAEs) = 18 Participants ; -; -
A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Phase 3; n=108; evaluation: not stated. Reported fields: Number of subjects with at least one adverse event = 46 Number of subjects ; -; -
A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome
Phase 3; n=174; evaluation: not stated. Reported fields: Number of New BCCs Per Participant(Mean) = 4.03 New basal cell carcinomas (Standard Deviation, 4.76); -; Number of New BCCs Per Participant(Mean) = 2.84 New basal cell carcinomas (Standard Deviation, 3.39)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Patidegib addresses Basal Cell Nevus Syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-01-27 | Marqeta Completes Acquisition of Power Finance, Inc. | Phase 3 | US$4.7M upfront; US$70.0M milestones; US$74.7M stated total |
| 2018-11-20 | LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases | Phase 2 | US$70.0M upfront; US$690.0M milestones; US$760.0M stated total |
| 2013-06-01 | INFINITY PHARMACEUTICALS, INC. entered into a license agreement with PellePharm, Inc., or PellePharm. | Phase 2 | US$50.5M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Treatment and prevention of basal cell carcinoma with topical composition comprising patidegib”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
